Gary Gilliland

D. Gary Gilliland, PhD MD, is Professor of Medicine at Harvard Medical School and an Investigator of the Howard Hughes Medical Institute. He is also an Associate Member of the Broad Institute of Harvard and MIT, Director of the Leukemia Program for the Dana-Farber/Harvard Cancer Center, and Director of the Cancer Stem Cell Program for the Harvard Stem Cell Institute. His research efforts have focused on the genetic basis of hematologic malignancies, with a goal on utilizing insights from these studies for clinical translational purposes. His research contributions have included the cloning of a spectrum of disease alleles associated with myeloproliferative disease, acute leukemias, and myelodysplastic syndromes using genetic and genomic approaches. Recent work is focused on programs that regulate self-renewal in normal and leukemic stem cells and the role of JAK2 in pathogenesis of polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. He received his PhD from the University of California at Los Angeles in 1980, his MD from the University of California at San Francisco in 1984. He trained in Internal Medicine at Brigham & Women's Hospital where he was also Chief Medical Resident, and completed fellowship training in Hematology at Brigham and Women's Hospital and in Medical Oncology at the Dana Farber Cancer Institute. He joined the faculty at Harvard Medical School in 1989.